Lead Product(s): Mesenchymal stem cells
Therapeutic Area: Immunology
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Avacta Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2020
The joint venture will develop a new class of MSCs that are primed to produce Affimer proteins to enhance the immune-modulatory effect when administered to patients.